KRAS and colorectal carcinoma: Interestingly, metabolic CRC subtype tumours (CMS3) have been characterized as those which harbor KRAS mutations, a mixed MSI status, low somatic copy number alterations (SCNA), and low CpG island methylator phenotype (CIMP).